– NEPTUNE WELLNESS SOLUTIONS STUDY ON OMEGA-3, RELEASED EXCLUSIVELY BY OXFORD PRESS –
LAVAL, QC, February 24, 2021 / PRNewswire / – Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company that focuses on natural, plant-based, sustainable and purposeful Product Concentrated -driven lifestyle brands, today announced groundbreaking research into the omega-3 fish oil intake, which forms the basis of its exclusive MaxSimil® product. The study was published in the Journal of Nutrition by the. released Oxford University Press.
MaxSimil® is a patented omega-3 fatty acid delivery technology that uses enzymes that mimick the natural human digestive system to pre-digest omega-3 fatty acids.
The study entitled “Pharmacokinetics of Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl ester, or Triglycerides in Adults in a Randomized Crossover Study ”- complements a growing body of research on Neptune’s patented MaxSimil® fish oils.
“This positions Neptune as a leader in the fast growing omega-3 ingredient market, which is expected to be USD. will achieve $ 8.5 Billions by 2025,” called Michael Cammarata, Chief Executive Officer and President of Neptune. “These results confirm Neptune’s mission to transform consumer habits through the use of innovative ingredients such as MaxSimil®, and we will continue to conduct research and studies to learn how best to introduce them into consumers’ everyday lives.”
The aim of the study was to compare the 24-hour area under the curve (AUC) of the plasma concentrations of EPA, DHA and EPA + DHA when provided esterified in monoglycerides (MAGs), ethyl esters (EEs) or triglycerides (TGs ), (primary endpoints) and assess their side effects over 24 hours (secondary endpoints).
For this research, the study was a randomized, triple-blinded, controlled crossover study. Eleven women and eleven men between the ages of 18 and 50 took a single oral dose of ∼1.2 g EPA and DHA, esterified in MAGs, EEs and TGs, with low-fat meals during the 24-hour sequence, in random order. -high.
Eleven blood samples were taken from each participant over 24 hours and the n-3 fatty acids (FA) in the plasma were quantified. Friedman’s paired ANOVA statistical rank test was used for pharmacokinetic parameters and a chi-square statistical test was used for side effects.
The report showed that the maximum plasma concentration of EPA (Cmax) in the MAG form was 3.5 and 1.3 times higher in the EE and TG forms, respectively (P = 0.0003, P <0.0001), which indicates a higher absorption capacity compared to standard fish oil. The effects of the EE and TG treatments did not differ. The MAG form was found to be just as safe as the EE and TG forms, with minimal reported side effects.
“This suggests that MaxSimil® fish oils bypass the first steps of digestion by providing easily absorbable forms of fats that can be absorbed directly into the intestinal tract,” said Cedrick Billequey, General Manager of the Neptune subsidiary Biodroga Nutraceuticals. “MaxSimil®’s monoglyceride fatty acids are absorbed even in the absence of digestive enzymes, making MaxSimil® a great solution for those suffering from digestive problems due to health problems, medication or age.”
The study was authored by Laurie Chevalier, Annick Vachon and Dr. Mélanie Plourde from the University of Sherbrooke in Québec, with her research supported and reviewed by Neptune Wellness Solutions Inc., Ingenutra, and SCF Pharma.
This study was registered at www.clinicaltrials.gov as NCT03897660.
To read the full report, click here. To read the summary, click here.
For more information on Neptune Wellness Solutions Inc. and MaxSimil®, please visit www.neptunecorp.com.
ABOUT NEPTUNE WELLNESS SOLUTIONS INC .:
Neptune Wellness Solutions is a unique global health and wellness company that is transforming consumer habits through the development and distribution of environmentally friendly, ethical and innovative consumer products. Neptune’s simultaneous focus on customer-centric B2C and B2B branding gives the company international reach and reach from its own and operated facilities that extract and create product formulations to retail spaces at leading global retailers.
Neptune’s diversified and fully integrated business model is driven by a disruptive spirit and focuses on natural, herbal, sustainable and purpose-driven lifestyle brands and the use of cannabinoids in household products to make them safer, healthier and more effective. The portfolio includes emerging brands such as Forest Remedies ™, Ocean Remedies ™, Neptune Wellness ™, Mood Ring ™ and OCEANO3 ™, which are prepared for rapid growth and expansion.
Backed by a cost-effective manufacturing and supply chain infrastructure that can be scaled up and down or into adjacent product categories to identify new innovation opportunities, Neptune quickly adapts to consumer preferences and demand, bringing its products as well as other Fortune 100s -Mark brands to market through strategic distribution partnerships, bulk retail partners, and e-commerce channels. Neptune is committed to its core mission of redefining health and wellness and helping humanity thrive by providing sustainable consumer-centric solutions. Further information is available at: www.neptunecorp.com
Statements in this press release that are not historical or current facts constitute “forward-looking statements” within the meaning of the United States and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that may lead to us Neptune’s actual results will differ materially from historical results or future results expressed or implied in such forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are asked to consider statements that include the terms “believes”, “believes”, “expects”, “intends”, “projects”, “anticipates”, ” will “,” “should” or “plans” be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
The forward-looking statements contained in this press release are expressly limited in their entirety by this cautionary note and the “Cautionary Note Regarding Forward-Looking Information” section in Neptune’s latest annual information form (the “AIF”), which is also part of Neptune’s Latest Annual Report on Form 40-F , which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml, and in the investor section of the Neptune website at www.neptunecorp.com. All forward-looking statements in this press release speak as of the date of this press release. Neptune undertakes no obligation to update such forward-looking statements as a result of new information, future events, or otherwise, except as required by law. The forward-looking statements contained herein include, but are not limited to, statements regarding the fulfillment of orders, the availability of products from Neptune’s suppliers and the anticipated use of funding proceeds, as well as other risks and uncertainties that may be described from time to time by Neptune Public Securities filings with the Securities and Exchange Commission and the Canadian Securities Commissions. Further information on these assumptions as well as risks and uncertainties can be found in the AIF under “Risk Factors”.
Neither NASDAQ nor the Toronto Stock Exchange accept responsibility for the adequacy or accuracy of this news release.
SOURCE Neptune Wellness Solutions Inc.